233 related articles for article (PubMed ID: 27303300)
41. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
42. Interactive mechanisms among pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide, and parathyroid hormone receptors in guinea pig cecal circular smooth muscle cells.
Motomura Y; Chijiiwa Y; Iwakiri Y; Ochiai T; Nawata H
Endocrinology; 1998 Jun; 139(6):2869-78. PubMed ID: 9607796
[TBL] [Abstract][Full Text] [Related]
43. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
44. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.
Vertongen P; Devalck C; Sariban E; De Laet MH; Martelli H; Paraf F; Hélardot P; Robberecht P
J Cell Physiol; 1996 Apr; 167(1):36-46. PubMed ID: 8698838
[TBL] [Abstract][Full Text] [Related]
45. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
46. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
[TBL] [Abstract][Full Text] [Related]
47. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
[TBL] [Abstract][Full Text] [Related]
48. The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration.
Cochaud S; Chevrier L; Meunier AC; Brillet T; Chadéneau C; Muller JM
Neuropeptides; 2010 Oct; 44(5):373-83. PubMed ID: 20638719
[TBL] [Abstract][Full Text] [Related]
49. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
Vertongen P; Camby I; Darro F; Kiss R; Robberecht P
Neuropeptides; 1996 Oct; 30(5):491-6. PubMed ID: 8923513
[TBL] [Abstract][Full Text] [Related]
50. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
[TBL] [Abstract][Full Text] [Related]
51. Pituitary adenylate cyclase-activating polypeptide regulates rat Leydig cell function in vitro.
Romanelli F; Fillo S; Isidori A; Conte D
Neuropeptides; 1997 Aug; 31(4):311-7. PubMed ID: 9308016
[TBL] [Abstract][Full Text] [Related]
52. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
53. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal peptide receptor expression in immortalized LHRH neurons.
Olcese J; McArdle CA; Middendorff R; Greenland K
J Neuroendocrinol; 1997 Dec; 9(12):937-43. PubMed ID: 9468019
[TBL] [Abstract][Full Text] [Related]
54. Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells.
Suzuki A; Kotoyori J; Oiso Y; Kozawa O
Cell Signal; 1994 Jan; 6(1):11-6. PubMed ID: 7912096
[TBL] [Abstract][Full Text] [Related]
55. Vasoactive intestinal polypeptide- and pituitary adenylate cyclase activating polypeptide-mediated control of catecholamine release from chromaffin tissue in the rainbow trout, Oncorhynchus mykiss.
Montpetit CJ; Perry SF
J Endocrinol; 2000 Sep; 166(3):705-14. PubMed ID: 10974664
[TBL] [Abstract][Full Text] [Related]
56. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
57. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on hormone secretion from sheep pituitary cells in vitro.
Sawangjaroen K; Anderson ST; Curlewis JD
J Neuroendocrinol; 1997 Apr; 9(4):279-86. PubMed ID: 9147291
[TBL] [Abstract][Full Text] [Related]
58. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
[TBL] [Abstract][Full Text] [Related]
59. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
60. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]